

**ALZHEIMER DISEASE BIOMARKER BASED ON CAROTID ARTERY
REACTIVITY**

MOHD AMINUDIN BIN JAMLOS

UNIVERSITI TEKNOLOGI MALAYSIA

ALZHEIMER DISEASE BIOMARKER BASED ON CAROTID ARTERY
REACTIVITY

MOHD AMINUDIN BIN JAMLOS

A thesis submitted in fulfilment of the
requirements for the award of the degree of
Master of Engineering (Biomedical)

Faculty of Biomedical Engineering and Health Sciences
Universiti Teknologi Malaysia

SEPTEMBER 2012

*Specially dedicated to my beloved mom and dad,
HjhSitiMeriam Bt. Hj Sam and HjJamlos Bin Baba,
my siblings and family, for their encouragement and support;
as well as my lovely wife, KhairunnisaBinti Ahmad and all my friends who always
inspired and motivated me along my excellent journey of education*

ACKNOWLEDGEMENT

In the name of Allah, Most Gracious, Most Merciful. Praise be to Allah, the Cherisher and Sustainer of the Worlds. With His permission I have completed my Master Degree of Biomedical Engineering and hopefully this thesis will benefit the development of the Ummah all over the world.

Special thanks as well to my project supervisor, Professor IrDr. Ing. EkoSupriyanto, for his guidance, motivations, support and constructive comments in accomplishing this project.

My family deserves special mention for their constant support and for their role of being the driving force towards the success of my project. My friends deserve recognition for lending a helping hand when I need them. I would also like to thank the wonderful members of CLEANER LAB; Mr. ImamulMuttakin, Mrs. Wan MahaniNurhafizah, Mr. Ng Kent Hoo, and Mr. Muhammad IzuddinAbdKadir, who have been extremely kind and helpful throughout my stay. “We don’t remember days, but we remember moments” and I had a great time and moments with all these guys during my study in UTM.

My sincere appreciation also goes to everyone whom I may not have mentioned above; who have helped directly or indirectly in the completion of my project. A million thanks for all.

ABSTRACT

Alzheimer disease (AD) is a progressive neurodegenerative disorder associated with the disruption of neuronal function. Carotid Artery Reactivity (CAR) is a new biomarker method for AD detection which provides various advantages as compared to existing detection method. Current developed methods have either radiation risk (positron emission tomography [PET] and computed tomography [CT] scanning), high cost and long scanning duration (magnetic resonance imaging [MRI]) or lack accuracy (electroencephalography [EEG]). New AD detection method could be implemented using ultrasound machine by assessing the carotid artery condition since the impairment of this artery leads to brain hypoperfusion, a clinical feature of AD. CAR allows normal functioning artery to dilate in order to permit more bloods flow into the brain. The three different variables utilized to study the CAR were the carotid artery blood flow velocity, its diameter and cross sectional area. Healthy people and Alzheimer patient are believed to have different CAR value. Hence, this study emphasized on finding the normal reactivity value belonging to healthy people and Alzheimer patient. This CAR value could be used to differentiate between healthy people and Alzheimer patient as the new method of detection. The studied subject consisted of 40 healthy people and 20 Alzheimer patients. All subjects had been scanned with ultrasound machine using Doppler and 3D technique before and after performed exercise to achieve 85% of their Maximal Heart Rate (MHR). Readings of each reactivity variables before exercise (rest) and after exercise (stimulated) were recorded to be analyzed to compare its percentage increment value (reactivity). Based on the results, Alzheimer patient recorded very low reactivity value which were 21% (blood flow velocity), 8.1% (diameter changes) and 16.67% (area changes) while normal reactivity recorded high reactivity value which were 109% (blood flow velocity), 22.2% (diameter changes) and 49.59% (area changes).

ABSTRAK

Penyakit Alzheimer merupakan gangguan neurodegenerative progresif yang dikaitkan dengan gangguan fungsi neuron. Kereaktifan karotid arteri sebagai kaedah 'biomarker' yang baru untuk pengesanan penyakit Alzheimer memberikan pelbagai kelebihan berbanding dengan kaedah-kaedah pengesanan pada masa kini. Kaedah pengesanan terkini berisiko tinggi (tomografi pelepasan positron dan imbasan tomografi berkomputer), kos yang tinggi dan tempoh pengimbasan panjang (pengimejan magnetik resonan) atau kurang ketepatan (elektroencephalografi). Pengesanan baru Alzheimer boleh dilakukan menggunakan mesin ultrasound melalui penilaian keadaan carotid arteri kerana kerosakan arteri ini membawa kepada hipoperfusi oksigen dalam otak, satu ciri klinikal Alzheimer. Kereaktifan karotid arteri membenarkan arteri yang berfungsi secara normal untuk mengembang bagi membenarkan lebih banyak darah mengalir ke dalam otak. Tiga ciri yang berbeza digunakan untuk mengkaji kereaktifan ini iaitu halaju darah carotid arteri, diameter dan luas keratan rentas. Orang yang sihat dan pesakit Alzheimer dipercayai mempunyai kereaktifan karotid arteri yang berbeza. Oleh itu, kajian ini memberi penekanan kepada penilaian kereaktifan dimiliki oleh orang sihat dan pesakit Alzheimer. Nilai ini boleh digunakan untuk membezakan antara orang yang sihat dan pesakit Alzheimer sebagai kaedah baru pengesanan. Subjek kajian ini terdiri daripada 40 orang yang sihat dan 20 pesakit Alzheimer. Kesemua subjek telah diimbas dengan mesin ultrasound yang menggunakan teknik 'Doppler' dan tiga dimensi sebelum dan selepas senaman untuk mencapai 85% Kadar Jantung Maksimum. Bacaan setiap ciri kereaktifan sebelum senaman (rehat) dan selepas senaman (dirangsang) diambil untuk dianalisis untuk dibandingkan nilai peratusan kenaikan (kereaktifan). Berdasarkan keputusan, pesakit Alzheimer mencatatkan kereaktifan nilai yang sangat rendah di mana 21% (halaju aliran darah), 8.1% (perubahan diameter) dan 16.67% (perubahan luas) manakala kereaktifan normal mencatatkan nilai kereaktifan tinggi di mana 109% (halaju aliran darah), 22.2% (perubahan diameter) dan 49.59% (perubahan luas).

TABLE OF CONTENT

| CHAPTER | TITLE | PAGE |
|----------|---------------------------------------|-------|
| | DECLARATION | ii |
| | DEDICATION | iii |
| | ACKNOWLEDGMENT | iv |
| | ABSTRACT | v |
| | ABSTRAK | vi |
| | TABLE OF CONTENTS | vii |
| | LIST OF TABLES | x |
| | LIST OF FIGURES | xii |
| | LIST OF SYMBOLS | xv |
| | LIST OF ABBREVIATIONS | xvi |
| | LIS OF APPANDICES | xviii |
| 1 | INTRODUCTION | 1 |
| | 1.1 Introductions | 1 |
| | 1.2 Study Background | 2 |
| | 1.3 Problem Statement | 3 |
| | 1.4 Objective | 5 |
| | 1.5 Scope and Limitation of the Study | 5 |
| | 1.6 Organization of the Thesis | 6 |
| 2 | LITERATURE REVIEW | 8 |
| | 2.1 Introductions | 8 |

| | | |
|----------|------------------------------------|-----------|
| 2.2 | Alzheimer Disease (AD) | 9 |
| 2.2.1 | AD Pathophysiology | 11 |
| 2.2.2 | Detection Method | 14 |
| 2.2.2.1 | Neuropsychological Test | 15 |
| 2.2.2.2 | Biochemical Marker | 17 |
| 2.2.2.3 | Diagnostic Imaging | 18 |
| 2.2.3 | Comparative Imaging | 22 |
| 2.2.4 | Risk Factor of AD | 25 |
| 2.2.4.1 | Age | 25 |
| 2.2.4.2 | Insulin Resistance/ Diabetes | 26 |
| 2.2.4.3 | Genetics | 26 |
| 2.2.5 | Symptoms of AD | 27 |
| 2.2.6 | Treatment and Prevention for AD | 28 |
| 2.3 | Cerebral Blood Flow | 29 |
| 2.4 | Brain Hypoperfusion | 31 |
| 2.5 | Carotid Artery | 34 |
| 2.5.1 | Anatomy | 34 |
| 2.5.2 | Carotid Artery Ultrasound | 36 |
| 2.5.2 | Carotid Artery Reactivity | 38 |
| 2.6 | Stress Test | 40 |
| 2.6.1 | Equipment and Protocol | 42 |
| 2.6.2 | Indication and Contraindication | 44 |
| 2.7 | Problems in Diagnosing AD | 46 |
| 3 | RESERCH AND METHODOLOGY | 47 |
| 3.1 | Introductions | 47 |
| 3.2 | Project Methodology and Flow Chart | 48 |
| 3.3 | Experimental Setup | 50 |
| 3.4 | Subject/Data Collection | 51 |
| 3.5 | Ultrasound Imaging Technique | 52 |
| 3.6 | Measurement | 53 |
| 3.7 | Data Analysis | 59 |

| | | |
|----------|--|------------|
| 4 | RESULT ANALYSIS AND DISCUSSION | 65 |
| 4.1 | Introductions | 65 |
| 4.2 | Heart Rate Measurement | 66 |
| 4.3 | Carotid Artery Blood Flow Velocity | 71 |
| 4.4 | Carotid Artery Diameter Changes Measurement | 76 |
| 4.5 | Carotid Artery Cross Sectional Area Changes Measurement | 81 |
| 4.6 | Overall Analysis of Carotid Artery Reactivity Measurement | 86 |
| 4.7 | Gender and Age Analysis of Carotid Artery Reactivity Measurement | 94 |
| 4.8 | Carotid Artery Reactivity Variables Correlation | 99 |
| 4.9 | Analysis of Stress Test | 103 |
| 5 | CONCLUSION | 108 |
| 6.1 | Overall Conclusion | 108 |
| 6.2 | Key Contribution | 109 |
| 6.3 | Future Research | 109 |
| | REFERENCES | 110 |
| | Appendices A1–A22 | 118-140 |

LIST OF TABLES

| TABLE NO. | TITLE | PAGE |
|------------------|---|-------------|
| 2.1 | Comparison of modalities for AD detection | 24 |
| 2.2 | CBF and HR reading according to level of exercise | 40 |
| 3.1 | Subject Details | 52 |
| 4.1 | Heart rate changes in young male subject | 66 |
| 4.2 | Heart rate changes in young female subject | 67 |
| 4.3 | Heart rate changes in old male subject | 68 |
| 4.4 | Heart rate changes in oldfemale subject | 69 |
| 4.5 | Heart rate changes in Alzheimer patient | 70 |
| 4.6 | Carotid artery blood flow velocity changes in normal young male | 71 |
| 4.7 | Carotid artery blood flow velocity changes in normal young female | 72 |
| 4.8 | Carotid artery blood flow velocity changes in normal old male | 73 |
| 4.9 | Carotid artery blood flow velocity changes in normal oldfemale | 74 |
| 4.10 | Carotid artery blood flow velocity changes in Alzheimer patient | 75 |
| 4.11 | Carotid artery diameter changes in normal young male | 76 |

| | | |
|------|---|-----|
| 4.12 | Carotid artery diameter changes in normal young female | 77 |
| 4.13 | Carotid artery diameter changes in normal old male | 78 |
| 4.14 | Carotid artery diameter changes in normal old female | 79 |
| 4.15 | Carotid artery diameter changes in Alzheimer patient | 80 |
| 4.16 | Carotid artery area changes in normal young male | 81 |
| 4.17 | Carotid artery area changes in normal young female | 82 |
| 4.18 | Carotid artery area changes in normal old male | 83 |
| 4.19 | Carotid artery area changes in normal old female | 84 |
| 4.20 | Carotid artery area changes in Alzheimer patient | 85 |
| 4.21 | Mean t-test and correlation table for carotid artery reactivity of normal and Alzheimer | 86 |
| 4.22 | Mean t-test table of normal and Alzheimer reactivity measurement | 94 |
| 4.23 | Reactivity variable correlation of normal and Alzheimer | 99 |
| 4.24 | Correlation between normal and Alzheimer heart rate towards reactivity variable | 103 |

LIST OF FIGURES

| FIGURE NO. | TITLE | PAGE |
|-------------------|--|-------------|
| 2.1 | Neuritic plaques made of amyloid-b (blue) and neurofibrillary tangles made of tau (brown) in Alzheimer's disease | 13 |
| 2.2 | Pick bodies and neurites made of tau (brown) in Pick's Disease | 13 |
| 2.3 | Electroencephalography test | 21 |
| 2.4 | Brain Waves | 22 |
| 2.5 | Human circulatory system | 33 |
| 2.6 | Carotid Artery Anatomy | 35 |
| 2.7 | Ultrasound Machine | 37 |
| 2.8 | Sheet of smooth muscle | 39 |
| 2.9 | Treadmill | 43 |
| 2.10 | Electronic Bicycle | 44 |
| 3.1 | Flow chart of overall process | 48 |
| 3.2 | Block diagram of experimental set up | 50 |
| 3.3 | Flow chart of carotid artery blood flow measurement | 54 |
| 3.4 | Flow chart of carotid artery diameter measurement | 55 |
| 3.5 | Flow chart of carotid artery cross sectional area measurement | 56 |
| 3.6 | Carotid artery blood flow velocity ultrasound image | 57 |
| 3.7 | Carotid artery diameter ultrasound image | 57 |
| 3.8 | Carotid artery cross sectional area ultrasound image | 58 |

| | | |
|---------|--|-----|
| 3.9(a) | Carotid artery blood flow velocity during rest | 60 |
| 3.9(b) | Carotid artery blood flow velocity during exercise | 60 |
| 3.10(a) | Carotid artery diameter during rest | 61 |
| 3.10(b) | Carotid artery diameter during exercise | 61 |
| 3.11(a) | Carotid artery cross sectional area during rest | 62 |
| 3.11(b) | Carotid artery cross sectional area during exercise | 62 |
| 4.1 | Bar chart of normal and Alzheimer carotid artery reactivity measurement | 86 |
| 4.2 | Graph of normal and Alzheimer velocity increment % | 88 |
| 4.3 | Graph of normal and Alzheimer diameter increment % | 88 |
| 4.4 | Graph of normal and Alzheimer area increment % | 89 |
| 4.5 | Correlation graph between normal and Alzheimer velocity increment percentage | 90 |
| 4.6 | Correlation graph between normal and Alzheimer diameter increment percentage | 90 |
| 4.7 | Correlation graph between normal and Alzheimer area increment percentage | 91 |
| 4.8 | Correlation graph between normal and Alzheimer heart rate increment percentage | 92 |
| 4.9 | Graph of normal and Alzheimer heart rate increment % | 93 |
| 4.10 | Graph of normal and Alzheimer velocity increment % | 95 |
| 4.11 | Graph of normal and Alzheimer diameter increment % | 95 |
| 4.12 | Graph of normal and Alzheimer area increment % | 96 |
| 4.13 | Bar chart of normal and Alzheimer reactivity measurement | 98 |
| 4.14 | Normal velocity and diameter correlation | 99 |
| 4.15 | Normal velocity and area correlation | 99 |
| 4.16 | Normal diameter and area correlation | 100 |
| 4.17 | Alzheimer velocity and diameter correlation | 100 |
| 4.18 | Alzheimer velocity and area correlation | 101 |

| | | |
|------|--|-----|
| 4.19 | Alzheimer diameter and area correlation | 101 |
| 4.20 | Normal heart rate correlation with blood flow velocity | 103 |
| 4.21 | Normal heart rate correlation with diameter | 104 |
| 4.22 | Normal heart rate correlation with area | 104 |
| 4.23 | Alzheimer heart rate correlation with blood flow velocity | 105 |
| 4.24 | Alzheimer heart rate correlation with area | 105 |
| 4.25 | Alzheimer heart rate correlation with diameter | 106 |

LIST OF SYMBOLS

| | | |
|-----------------------|---|-----------------------|
| <i>Bt/m</i> | - | Beat per minute |
| <i>CI</i> | - | Confidence Interval |
| <i>Cm/s</i> | - | Centimeter per second |
| <i>DR</i> | - | Dynamic Range |
| <i>Hz</i> | - | Hertz |
| <i>MHz</i> | - | Mega Hertz |
| <i>Mm</i> | - | Millimeter |
| <i>Mm²</i> | - | Millimeter per square |
| <i>Mm Hg</i> | - | Substrate thickness. |
| <i>p</i> | - | Significant value |
| <i>r</i> | - | Correlation |

LIST OF ABBREVIATIONS

| | | |
|-----------------|---|--|
| $A\beta$ | - | β -Amyloid |
| AD | - | Alzheimer Disease |
| AGD | - | Argyrophilic Grain Disease |
| ALZM | - | Alzheimer |
| APOE | - | Apolipoprotein E |
| APP | - | Amyloid Precursor Protein |
| ASL | - | Arterial Spin Labeling |
| BOLD | - | Blood Oxygenated Level Dependent |
| CAD | - | Coronary Artery Disease |
| CANTAB | - | Cambridge Neuropsychological Test Automated Battery |
| CAS | - | Carotid Artery Structure |
| CAR | - | Carotid Artery Reactivity |
| CBD | - | Corticobasal Degeneration |
| CBF | - | Cerebral Blood Flow |
| CCA | - | Common Carotid Artery |
| CO | - | Cardiac Output |
| CO ₂ | - | Carbon Dioxide |
| CSF | - | Cerebrospinal Fluid |
| CT | - | Computed Tomography |
| CVR | - | Cerebral Vessel Reactivity |
| DTI | - | Diffusion Tensor Imaging |
| DWI | - | Diffusion Weighted Imaging |
| EEG | - | Electroencephalography |

| | | |
|--------|---|---|
| EF | - | Ejection Fraction |
| ERPS | - | Event-related Potentials |
| FDG | - | Fluorodeoxyglucose |
| fMRI | - | Functional Magnetic Resonance Imaging |
| HR | - | Heart Rate |
| HRmax | - | Maximum Heart Rate |
| MAP | - | Mean Arterial Pressure |
| MCA | - | Middle Cerebral Artery |
| MCI | - | Mild Cognitive Impairment |
| MRI | - | Magnetic Resonance Imaging |
| MTL | - | Medial Temporal Lobe |
| NFT | - | Neurofibrillary Tangles |
| NMDA | - | N-Methyl-D-Asparatic Acid |
| NOF | - | Normal Old Female |
| NOM | - | Normal Old Male |
| NSAID | - | Nonsteroidal Anti-Inflammatories |
| NYF | - | Normal Young Female |
| NYM | - | Normal Young Male |
| PAL | - | Paired Associative Learning |
| PET | - | Positron Emission Tomography |
| PSP | - | Progressive Supranuclear Palsy |
| QEEG | - | Quantitative Electroencephalography |
| RAVLT | - | Rey Auditory-Verbal Learning Test |
| SMA | - | Smooth Muscle Alpha Actin |
| SPECT | - | Single Photon Emission Tomography |
| SPSS | - | Statistics Package For Social Science |
| TCD | - | Transcranial Doppler |
| TICS-m | - | Telephone Interview for Cognitive Status-Modified |
| WMHI | - | White Matter Hyperintensity |
| WMS | - | Wechsler Memory Scale |
| 3D | - | Three Dimensions |
| 7MS | - | 7-minute Screen |

LIST OF APPANDICES

| APPENDIX | TITLE | PAGE |
|-----------------|---------------------------------|-------------|
| A | List of publications and awards | 118 |
| B | SPSS calculation sheet | 119 |
| C | Subject consent and detail form | 138 |

CHAPTER 1

INTRODUCTION

1.1 Introduction

This thesis proposes the novel design of experiment and new specific formula for Alzheimer Disease (AD) biomarker. This work involves new formula to evaluate carotid artery structure (CAS) of healthy people and Alzheimer patient before and after having adequate exercise in order to reach 85% of maximum heart rate to come out with specific value to distinguish the people with and without AD. Ultrasound machine with Doppler and three dimensions (3D) technique applied on human carotid artery within this new method is proven safe, cheap, fast and accurate compared to current methods to detect AD.

Overall, this thesis describes a new method to detect AD including the literature review on AD, experimental set up until the carotid artery reactivity measurement process. In first chapter, brief background of the project is discussed, providing problem statements, objectives, methodology and scopes of work in conducting research including project's possible outcomes and contributions as well as thesis organization.

1.2 Study Background

AD is a progressive neurodegenerative disorder associated with disruption of neuronal function [1]. It reduces the capability of brain to perform its regular activity including daily routine such as bathing, eating, drinking and many more. AD becomes worse as it progresses and eventually able in leading to death. The common symptoms include disturbances in memory, attention, orientation, changes in personality, language difficulties and walking problem as well as movement limitation. AD usually begins after age of 60 and the risk increases with age. Due to the expectation of increasing in life span particularly in developed countries' citizens, more people will have higher risk and potential to get AD [2]. AD has affected 24.3 million people worldwide in 2010 with increment around 4.6 million yearly [3]. Based on the statistic produced by Health Ministry of Malaysia, it is estimated around 63,000 people having AD and expected to reach 127,000 in the next 10 year [4].

Mild cognitive impairment (MCI) is among the earliest sign and symptom of AD [5]. MCI occurred due to brain hypoperfusion where the amount of blood flown toward brain is insufficient or inadequate with the need of brain cell in performing cognitive activities. According to Torre J. C. et al, performances of cognitive tasks require the delivery of adequate oxygen and glucose toward specific regions of the brain. Any insufficiency of oxygenated blood occurred especially in the older brain resulted in cognitive dysfunction. Brain hypoperfusion could be realized from variety pathology within carotid artery such as atherosclerosis, wall hardening and stenosis that lead to carotid artery impairment [6]. Hence, it is important to evaluate carotid artery condition accurately and efficiently to ensure the artery functions normally and free from any pathology.

Previously, in vitro studies found that one of the best methods to evaluate vessel function is on its contractility through measurement of cerebral vessel reactivity (CVR). Thus, a lot of new techniques have been explored to study vascular function based on its reactivity including diffusion weighted imaging (DWI), diffusion tensor imaging (DTI), arterial spin labeling (ASL) and blood oxygenated level dependent (BOLD) [7]. However, Doppler imaging technique using ultrasound

machine is the most suitable one compared to other methods since this modality has been used safely, accurately, cost effectively and quickly in evaluating carotid artery structure.

1.3 Problem Statement

New biomarker method for AD detection is very essential in treating AD where treatment in the early stage is very efficient especially before any clinical symptoms shown [8]. Ideally, with the early detection of AD, it should be possible to diagnose AD earlier or at a stage at which neurons are not irreversibly impaired by the disease process yet and have the potential to be treated [9]. A lot of imaging modalities with different techniques have been explored to detect AD biomarker. However, each of the techniques have its own weaknesses where high risk (positron emission tomography [PET] and computed tomography [CT] scanning), high cost and long scanning duration (magnetic resonance imaging [MRI]) or not accurate enough (electroencephalography [EEG]) [3]. However, the ultimate goal of using new method for diagnosing AD is not to replace other techniques but to add to the consistency and reliability of established indicators across a variety of tests [1].

Apart from that, vascular abnormalities has great potential to lead vascular dysfunction which can stimulate synaptotoxic B-amyloid (*Ab*) accumulation in the brain. This is considered as the central process for AD. Previous studies which applied measurement of resting cerebral blood flow (CBF) or CBF changes during active condition are not an accurate indicator to assess vascular function. This method however is more sensitive in determining neural activity rather than evaluating vessel properties. Hence, it is highly recommended to investigate on contractility of the cerebral vessel or CVR [7]. Hence, in this research, carotid artery reactivity is applied in evaluating its vascular function since Kolb B. et al found that carotid artery blood flow could replace the cerebral blood flow in evaluating cerebral vessel reactivity [10].

As mentioned before, brain hypoperfusion could be realized from variety pathologies within the heart and carotid artery that can critically reduce blood flow to the healthy and elderly brain. It is supported by Torre J. C. et al where asymptomatic and symptomatic carotid artery narrowing resulted in cognitive decline due to cerebral perfusion reduction [6]. Hence, it is suggested to do more research on carotid artery at especially on its structure and function. This study therefore emphasized on the characterization of the carotid artery including the blood flow velocity and diameter as well as cross sectional area.

Apart from that, preliminary results have shown that there are varieties of influencing factors for CVR. They are acetazolamide, CO₂ [11] and exercise [12]. All of the study results shown significant increment in cerebral blood flow after being stimulated with influencing factor compared to under normal condition [11, 13]. This is because the stimulators have dilated the vessel enables the blood to flow easily, freely and faster. Most of the current study using acetazolamide and admission of CO₂ which is still considered as high risk and dangerous to the patient or subject. Therefore, this study used the exercise method which is safe and low risk to be applied to the human as the influencing factor to dilate the carotid artery. However, CO₂ admission and injection of acetazolamide still being used in other study only for mice usage.

1.4 Objective

The main objectives of this study are as follows:

- i. Investigate correlation of ultrasound carotid blood flow (CBF) and carotid artery structure (CAS) between normal people and Alzheimer patient.
- ii. Develop a new biomarker method for AD detection.

1.5 Scope and Limitation of the Study

The main scopes of this study are:

- i. Analytics and Statistics Correlation between CBF (Carotid Blood Flow), CAS (Carotid Artery Structure), CAR (Carotid Artery Reactivity) and AD (Alzheimer Diseases).
- ii. Sensitivity and resolution of ultrasound for CBF and CAS measurement.
- iii. Correlation between AD parameter in human.
- iv. Effect of stress test in human CAS and CAR value.

The work scopes are to investigate the correlation among CBF, CAS, CAR and AD. In this research, ultrasound imaging applied to measure carotid artery blood flow, its diameter as well as the cross sectional area in order to develop new AD biomarker. The characterization of carotid artery structure affected in AD among human is done. The characterizations consist of the velocity of carotid artery and resolution of carotid structure. Both results before and after being stimulated by adequate exercise are compared to find differences and ratio that is used to create new formula based on CAR to categorize group of Alzheimer and non Alzheimer.

The limitations of this study are:

- i. Getting full cooperation from Alzheimer patient since they tend to forget the instructions given earlier during the experiment process.
- ii. There are multiple factors can reduce the blood flow to the brain. However, this research only focuses on carotid artery impairment.
- iii. Bigger size of subject especially Alzheimer patient.
- iv. This study focused only on evaluating carotid artery using ultrasound machine.

1.6 Organization of the Thesis

This thesis is divided into five chapters that describe all the work done for this study. The first chapter consists of the introduction, study background, problem statement, objectives, scope and limitation of the study. Chapter 2 is the literature review that explains literature about Alzheimer Disease and Carotid Artery Reactivity. Details of Alzheimer Disease introduced and explained including its definition, factors of cause, symptoms, statistics, treatment and precautions measurements. Apart from that, carotid artery structure is also viewed so that the relation of carotid artery and AD is clearly understood. Variety techniques of carotid artery imaging using MRI, CT Scan and ultrasound machine to evaluate carotid artery structure and its functions are described as well. Carotid Artery Reactivity which the proposed method in this research for AD early detection also being explain in chapter 2. Some overview of previous studies is presented too.

Research Methodology which covers experimental design and experimental set up is presented in chapter 3. In this chapter, research flow, design methodology and data collection method is briefly described. The research flow described the characterization of carotid artery reactivity in Alzheimer patient and normal people. This chapter also presents the measurement process of carotid artery reactivity of Alzheimer patient and normal people. The measurement results, analysis and discussion are presented in chapter 4. The results such as carotid artery blood flow,

its diameter and area are clearly presented. The results belong to Alzheimer patient and normal people are analyzed to come up with specific formula to be used as an AD early detection indicator. A discussion of the results including the accuracy, error, and difficulty are completely presented.

Finally, as the last chapter, chapter 5 covered the conclusion part. This chapter concludes the findings of the project, stated some key of contributions and provides recommendations for future work.

REFERENCES

1. Prince, S. E., Woo, S., Doraiswamy, P. M. and Petrella, J. R. Functional MRI in the early diagnosis of Alzheimer's disease: is it time to refocus?. *Expert Rev. Neurotherapeutics*, 2008. (8): 169-175.
2. Mueller, S. G., Weiner, M. W., Thal, L. J, Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., Toga, A. W. and Beckett, L., *Alzheimer's Disease Neuroimaging Initiative*, (2008). University of California, San Francisco, California, USA.
3. Yusoff, S. (2009). *Management of Dementia*. (2nd ed.). Putrajaya: Ministry of Health Malaysia.
4. "Patient Statistics", (2010) Putrajaya: Ministry of Health Malaysia.
5. Grundman, M., Petersen, R. C., Ferris, S. H., Thomas, R. G., Aisen, P. S., Bennett, D. A., Foster, N. L, Clifford, R. Jack, C. R., Galasko, D. R., Doody, R., Kaye, J, Sano, M., Mohs, R., Gauthier, S., Kim, H. T., Jin, S., Arlan, N., Schultz, A. N., Schafer, K., Mulnard, R., Dyck, C. H., Mintzer, J., Zamrini, E. Y., Weiner, D. C. and Thal, L. J. Mild Cognitive Impairment Can Be Distinguished From Alzheimer Disease and Normal Aging for Clinical Trials. *Arch Neurol*, 2004. (61): 59-66.
6. Torre. J. C. Carotid Artery Ultrasound and Echocardiography Testing to Lower the Prevalence of Alzheimer's Disease. *Journal of Stroke and Cerebrovascular Diseases*, 2009. (18): 319-328.

7. Yeshuvath, U. S., Uh, J., Cheng, Y., Cook, K. M., Weiner, M., Arrastia, R. D., Osch, M. V. and Lu, H., Forebrain-dominant deficit in cerebrovascular reactivity in Alzheimer's disease. *Neurobiology of Aging*, 2010. (2): 1-8.
8. Morris, J. C., Storandt, M., Miller, P., McKeel, D. W., Price, J. L., Rubin, E. H. and Berg, L. Mild Cognitive Impairment Represents Early-Stage Alzheimer Disease. *Arch Neurol*, 2001. (58): 397-405.
9. Mueller, S. G., Weiner, M. W., Thal, L. J, Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., Toga, A. W. and Beckett, L. Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI). *Alzheimer's & Dementia*, 2005. (1): 55-66.
10. Kolb, B., Diane, L. and Rotella, S. H. M. Frequency response characteristic of cerebral blood flow autoregulation in rats. *Am J Physiol Heart Circ Physiol*, 2007. (292): 432-438.
11. Scwertfeger, N., Neu, P., Schlattmann, P., Lemke, H., Heuser, I. and Bajbouj, M. Cerebrovascular reactivity over time course in healthy subjects. *Journal of the Neurological Sciences*, 2006. (249): 135-139.
12. Ogoh, S., Dalsgaard, M. K., Secher, N. H. and Raven, P. B., Dynamic blood pressure control and middle cerebral artery mean blood velocity variability at rest and during exercise in humans. *Acta Physiol*, 2007. (191): 3-14.
13. Goedert, M. and Spillantini, M. G. A Century of Alzheimer's Disease. *Science*, 2006. (314): 777-781.
14. Maslow, K. 2008 Alzheimer's disease facts and figures. *Alzheimer's & Dementia*, 2008. 110-133.
15. Mebane-Sims, I. 2009 Alzheimer's disease facts and figures. *Alzheimer's & Dementia*, 2009. 234-270.

16. Lopez, O. L., Schwam, E., Cumming, J., Gauthier, S., Jones, R., Wilkinson, D., Waldemar, G., Zhang, R. and Schindler R. Predicting cognitive decline in Alzheimer's disease: An integrated analysis. *Alzheimer's & Dementia*, 2010. (6): 431–439.
17. Carrillo, M. C., Blackwell, A., Hampel, H., Lindborg, J., Sperling, R., Schenk, D., Jeffrey, J. Seigny, J. J., Ferris, S., Bennett, D. A., Craft, S., Hsu, T. and Klunk, W. Early risk assessment for Alzheimer's disease. *Alzheimer's & Dementia*, 2009. 182–196.
18. Wong, S. H., Wong, S. H., Rajikan, R., Das, S., Yusoff, N. A., Lee, L. K., Aziz, S. A., Sakian, N. I. and Shahar, S. Antioxidant Intake And Mild Cognitive Impairment Among Elderly People In Klang Valley: A Pilot Study. *Universiti Sains Malaysia*, 2010. (39): 689–696.
19. Tarawneh, R. and Holtzman, D. M., Biomarkers in translational research of Alzheimer's Disease. *Neuropharmacology*, 2010. (59): 310-322.
20. Bell, R. D. and Zlokovic, B.V. Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer's disease. *Acta Neuropathol*, 2009. (118): 103–113.
21. Wisniewski, T. M. and Sadowski, M. (2004). *100 Questions & Answers about Alzheimer Disease*. Canada: Jones and Bartlett Publishers Inc.
22. Chow, N., Bell, R. D., Deane, R., Streb, J. W., Chen, J., Brooks, A., Nostrand, W. V., Miano, J. M. and Zlokovic, B. V. Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer's phenotype. *PNAS*, 2007. (104): 823-828.
23. Dean, C. (2004). *The Everything Alzheimer Book*. United State of America: F+W Publications Inc.

24. Silvestrini, M., Gobbi, B., Pasqualetti, P., Bartolini, M., Baruffaldi, R., Lanciotti, C., Cerqua, R., Altamura, C., Provinciali, L. and Vernieri, F. Carotid atherosclerosis and cognitive decline in patients with Alzheimer's disease. *Neurobiology of Aging*, 2009. (30): 1177–1183.
25. Khachaturian, Z. S. Diagnosis of Alzheimer's disease: Two decades of progress. *Alzheimer's & Dementia*, 2005. (1): 93–98.
26. Thal, L. J., Kantarci, K., Reiman, E. M., Klunk, W. E., Weiner, M. W., Zetterberg, H., Galasko, D., Pratico, D., Griffin, S., Schenk, D. and Siemers, E. The Role of Biomarkers in Clinical Trials for Alzheimer Disease. *Alzheimer Dis. Assoc Disord*, 2006. (20): 6–15.
27. Schapiro, R. C., Fagan, A. M. and Holtzman, D. M. Biomarkers of Alzheimer's disease. *Neurobiology of Disease*, 2009. (35): 128–140.
28. Lehericy, S., Marjanska, M., Mesrob, L., Sarazin, M. and Kinkingnehun, S. Magnetic resonance imaging of Alzheimer's disease. *Eur Radiol*, 2007. (17): 347–362.
29. Yamasaki, T., Muranaka H., Kaseda, Y., Mimori, Y. and Tobimatsu, S. Understanding the Pathophysiology of Alzheimer's Disease and Mild Cognitive Impairment: A Mini Review on fMRI and ERP Studies. *Neurology Research International*, 2012. (71): 1-10.
30. Schuff, N. and Zhu, X. P. Imaging of mild cognitive impairment and early dementia. *The British Journal of Radiology*, 2007. (80): 109–114.
31. Marieb, E. N. and Hoehn K. (2007). *Human Anatomy & Physiology*. (7th Ed.). Pearson Education Inc.
32. Wierenga, C. E. and Bondi, M. W. Use of Functional Magnetic Resonance Imaging in the Early Identification of Alzheimer's Disease. *Neuropsychol Rev*, 2007. (17): 127-143.

33. Mitschelen, M., Garteiser, P., Carnes, B. A., Farley, J. A., Doblus, S., Demoe, J. H., Warrington, J. P., Yan, H., Nicole, M. M., Towner, R. and Sontag, W. E. Basal and hypercapnia-altered cerebrovascular perfusion predict mild cognitive impairment in aging rodents. *Neuroscience*, 2009. (164): 918–928.
34. Mitsuhashi, N., Onuma, T., Kubo, S., Takayanagi, N., Honda, M. and Kawamori, R. Coronary Artery Disease and Carotid Artery Intima-Media Thickness in Japanese Type 2 Diabetic Patients. *Diabetes care*, 2002. (25): 8-14.
35. Virmani, R., Burke, A., Ladich, E., Kolodgie, F. D., Pathology of carotid artery atherosclerosis disease. Carotid Disease: The Role of Imaging in Diagnosis and Management. *Cambridge University Press*.
36. Rostrup, E., Law, I., Blinkenberg, M., Larsson, H. B. W., Born, A. P., Holm, S. and Paulson, O. B. Regional Differences in the CBF and BOLD Responses to Hypercapnia: A Combined PET and fMRI Study. *NeuroImage*, 2000. (11): 87–97.
37. Jamlos, M. A. and Supriyanto, E. AD Early Detection: Carotid Artery Reactivity Comparison between Healthy Young and Aged People. *International Journal of Biology and Biomedical Engineering*, 2012. 1(6): 51-60.
38. Maslow, K., 2010 Alzheimer's disease facts and figures. *Alzheimer's & Dementia*, 2010. (23): 158–194.
39. Kalaria, R. N. Cerebral Vessels in Ageing and Alzheimer's Disease. *Pharmacol. Ther*, 1996. (72): 193-214.

40. Gauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., Belleville, S., Brodaty, H., Bennett, D., Chertkow, H., Cummings, J. L., Leon, M., Feldman, H., Ganguli, M., Hampel, H., Scheltens, P., Tierney, M. C., Whitehouse, P. and Winblad, B., Mild cognitive impairment. *Lancet*, 2006. (367): 1262–70.
41. Goode, S. D., Krishna, S., Alexakis, C., Mahajan, R. and Auer, D. P. Precision of Cerebrovascular Reactivity Assessment with Use of Different Quantification Methods for Hypercapnia Functional MR Imaging. *AJNR Am J Neuroradiol*, 2009. (309): 72–77.
42. Bodo, M., Pearce, F. J. and Armonda, R. A. Cerebrovascular reactivity: rat studies in Rheoencephalography. *Physiol. Meas*, 2004. (25): 1371–1384.
43. Yeshuvath, U. S., Amezcuaa, K. L., Varghesea, R., Xiaob, G. and Lua, H, On the assessment of cerebrovascular reactivity using hypercapnia BOLD MRI. *NMR Biomed*, 2009. (22): 779-786.
44. Tortora, G. J. and Grabowski, S.R. (2003) *Principles of Anatomy And Physiology*. (10th Ed.). United States of America: John Wiley & Sons, Inc.
45. Sobieszczyk, P. and Beckman. J. Carotid Artery Disease. *Circulation*, 2006. (114): 244-247.
46. Faiz, O. and Moffat, D. (2002). *Anatomy at a Glance*. Blackwell Science Ltd.
47. Bontrager, K. L. and Lampignano, J. P. (2005). *Radiographic Positioning and Related Anatomy*. (6th Ed.). Mosby Inc.
48. Gutierrez, M. A., Pilon, P. E., Lage, S. G., Kopel, L., Carvalho, R. T. and Furuie, S. S. Automatic Measurement of Carotid Diameter and Wall Thickness in Ultrasound Images. *Computers in Cardiology*, 2002. (29): 359–362.

49. Romero, J. R., Beiser, A., Seshadri, S., Benjamin, E. J., Polak, J. F., Vasan, R. S., Au, R., DeCarli, C. and Wolf, P. A. Carotid Artery Atherosclerosis, MRI Indices of Brain Ischemia, Aging, and Cognitive Impairment, The Framingham Study. *Stroke*, 2009. (40): 1590-1596.
50. Grant, E. G., Carol, B. Benson, C. B., Moneta, G. L., Andrei, V. Alexandrov, A. V. J., Baker, D., Bluth, E. I., Carroll, B. A., Eliasziw, M., Gocke, J., Hertzberg, B. S., Katanick, S., Needleman, L., Pellerito, J., Polak, J. F., Rholl, K. S., Wooster, D. L. and Zierler, E. Carotid Artery Stenosis: Gray-Scale and Doppler US Diagnosis. *Radiology*, 2003. (229): 340–346.
51. Hesse, B, Gil, K. T., Cuocolo, A., Anagnostopoulos, C., Bardie, M., Bax, J., Bengel, F., Sokole, E. B., Davies, G., Dondi, M., Edenbrandt, L., Franken, P., Kjaer, A., Knuuti, J., Lassmann, M., Ljungberg, M., Marcassa, C., Marie, P. Y., McKiddie, F., O'Connor, M., Prvulovich, E., Underwood, R. and Eck-Smit, B. V. EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology. *European Journal of Nuclear Medicine and Molecular Imaging*, 2005. (32): 855-897.
52. Tanaka, H., Monahan, K. D. and Seals, D. R. Age-Predicted Maximal Heart Rate Revisited. *Journal of the American College of Cardiology*, 2001. (37): 153-157.
53. Henzlova, J. M., Cerqueira, M. D., Hansen, C. L., Taillefer, R. and Yao, S. S, Asnc Imaging Guidelines For Nuclear Cardiology Procedures Stress Protocols and Tracers. *American Society of Nuclear Cardiology*, 2009. (10): 9062-9075.
54. Chai, H. Y, Wee, L. K. and Supriyanto, E. Ultrasound Images Edge Detection using Anisotropic Diffusion in Canny Edge Detector Framework. *WSEAS Transaction*, 2011. (8): 1555-1557.

55. Hafizah, M., Kok, T. and Supriyanto, E. Development of 3D Image Reconstruction Based On Untracked 2D Fetal Phantom Ultrasound Images using VTK. *WSEAS Transactions on Signal Processing*, 2010. (6): 40-46.
56. Yagel, S. and Valsky, D. V. From anatomy to function: the developing image of ultrasound evaluation. *Ultrasound Obstet Gynecol*, 2008. (31): 615–617.
57. Nishime, E. O., Cole, C. R., Blackstone, E. H., Pashkow, F. J. and Lauer, M. S. Heart Rate Recovery and Treadmill Exercise Score as Predictors of Mortality in Patients Referred for Exercise ECG. *JAMA*, 2000. (284): 1392-1398.
58. Jamlos, M. A. and Supriyanto, E. Carotid Artery Reactivity Measurement among Healthy Young People Based On Optimized Ultrasound Images. *International Journal of Biology and Biomedical Engineering*, 2011. 4(5): 209-220.